Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864913 · ClinicalTrials.gov registry record · Early Phase 1
Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT03864913 is a Early Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 26 participants.
The verdict
NCT03864913, a Early Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The trial studies the efficacy of subcutaneous (SQ) testosterone compared to intramuscular (IM) testosterone therapy during the first 6 months of pubertal induction in transgender male adolescents. Describes rate of adverse effects, masculinizing effects and quality of life while receiving testosterone. Evaluates clinic utilization required for testosterone therapy.
Interventions
- DRUG Testosterone injection
- BEHAVIORAL PedsQL questionnarie
- OTHER Masculinizing effects questionnaire
- OTHER Medication experience questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2019-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03864913
The ClinicalTrials.gov registry entry for NCT03864913 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Testosterone injection is the first listed.
NCT03864913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03864913 about?
NCT03864913 is a clinical study titled "Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents". The trial studies the efficacy of subcutaneous (SQ) testosterone compared to intramuscular (IM) testosterone therapy during the first 6 months of pubertal induction in transgender male adolescents. Describes rate of adverse effects, masculinizing effects and quality of life while receiving testoster...
What is the current status of trial NCT03864913?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2018-01-26. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT03864913?
The interventions under investigation include: Testosterone injection (DRUG), PedsQL questionnarie (BEHAVIORAL), Masculinizing effects questionnaire (OTHER), Medication experience questionnaire (OTHER).
Who is sponsoring clinical trial NCT03864913?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.